The role of F-18-fluorothymidine PET in oncology

被引：19
作者：
Bertagna F. [1 ]
Biasiotto G. [2 ]
Giubbini R. [1 ]
机构：
[1] Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, 25123 Brescia, P.le Spedali Civili
[2] Biomedical Technology Department, University of Brescia, Brescia
来源：
Clinical and Translational Imaging | 2013年 / 1卷 / 2期
关键词：
3′-Deoxy-3′-18-fluorothymidine; Oncology; Positron emission tomography/computed tomography;
D O I：
10.1007/s40336-013-0014-2
中图分类号：
学科分类号：
摘要：
3′-deoxy-3′-([18F]Fluoro)-fluorothymidine, (18F-FLT) is a fluorinated tracer which has been proposed as an imaging biomarker of cell proliferation. The aim of this review is to provide an overall evaluation and description of the diagnostic role of 18F-FLT PET or PET/CT in oncology imaging and clinical practice. A comprehensive computer literature search of the PubMed/Medline databases revealed 371 articles. After reviewing the titles and abstracts, 285 articles were excluded, mainly because the reported data were not within the field of interest; 86 articles were selected. The overall assessment of the published studies showed marked heterogeneity both of the tumors analyzed and of the reasons for evaluation (diagnosis, staging, restaging, and therapy response evaluation). The tumor or organ most frequently analyzed was the lung, in 19 studies; the digestive tract was analyzed in 17 papers, brain tumors in 15, head and neck tumors in nine, myeloproliferative/lymphoproliferative diseases in nine, and breast cancer in six. Eleven studies dealt with the other forms of tumor (including melanomas, sarcomas, ovarian cancer, uterine cancer, germ cell tumors, and neuroendocrine tumors). Although no high-quality evidence could be derived on the role of 18F-FLT PET in oncology imaging, because of the extreme heterogeneity between the studies (with regard to the tumors evaluated, the reasons for performing the evaluations, and the devices and methodologies used), the limited number of studies per tumor type, and the very low number of patients enrolled in each study, these preliminary results seem to indicate a promising role for this tracer in oncology imaging, especially in therapy response evaluation and in brain tumors; it is also associated with a lower rate of false-positive results due to inflammation. Further studies are needed to confirm these preliminary results, and larger trials are desirable to establish the definitive diagnostic role of 18F-FLT in oncological clinical practice, considering its usefulness in relation to and in comparison with the already well-established 2-([18F]Fluoro)-2-deoxy-D-glucose, (18F-FDG), its importance in terms of cost-effectiveness, and its correct position in the diagnostic flow-chart for each tumor type. © 2013 Italian Association of Nuclear Medicine and Molecular Imaging.
引用
收藏
页码：77 / 97
页数：20
相关论文
共 104 条
  • [1] Rasey J.S., Grierson J.R., Wiens L.W., Kolb P.D., Schwartz J.L., Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells, J Nucl Med, 43, pp. 1210-1217, (2002)
  • [2] Flexner C., van der Horst C., Jacobson M.A., Powderly W., Duncanson F., Ganes D., Barditch-Crovo P.A., Petty B.G., Baron P.A., Armstrong D., Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials, J Infect Dis, 170, pp. 1394-1403, (1994)
  • [3] Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., Obradovich J.E., Muzik O., Mangner T.J., Imaging proliferation in vivo with [F-18]FLT and positron emission tomography, Nat Med, 4, pp. 1334-1336, (1998)
  • [4] Shields A.F., PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls, J Nucl Med, 44, pp. 1432-1434, (2003)
  • [5] Bading J.R., Shields A.F., Imaging of cell proliferation: status and prospects, J Nucl Med, 49, SUPPL. 2, (2008)
  • [6] Buchmann I., Neumaier B., Schreckenberger M., Reske S., [18F]3′-deoxy-3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations-a pilot study, Cancer Biother Radiopharm, 19, pp. 436-442, (2004)
  • [7] Buck A.K., Bommer M., Stilgenbauer S., Juweid M., Glatting G., Schirrmeister H., Mattfeldt T., Tepsic D., Bunjes D., Mottaghy F.M., Krause B.J., Neumaier B., Dohner H., Moller P., Reske S.N., Molecular imaging of proliferation in malignant lymphoma, Cancer Res, 66, pp. 11055-11061, (2006)
  • [8] Alauddin M.M., Positron emission tomography (PET) imaging with 18F-based radiotracers, Am J Nucl Med Mol Imaging, 2, pp. 55-76, (2012)
  • [9] Pascali C., Bogni A., Fugazza L., Cucchi C., Crispu O., Laera L., Iwata R., Maiocchi G., Crippa F., Bombardieri E., Simple preparation and purification of ethanol-free solutions of 3′-deoxy-3′-[18F]fluorothymidine by means of disposable solid-phase extraction cartridges, Nucl Med Biol, 39, pp. 540-550, (2012)
  • [10] Wilson I.K., Chatterjee S., Wolf W., Synthesis of 3′-fluoro-3′-deoxythymidine and studies of its 18F-radiolabeling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against AIDS, J Fluorine Chem, 55, pp. 283-289, (1991)
12345678910